From mysteries to medicines

Drug development for fibrodysplasia ossificans progressiva

Frederick S. Kaplan, Robert Pignolo, Eileen M. Shore

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Introduction: Fibrodysplasia ossificans progressiva (FOP) is the most disabling disorder of skeletal metamorphosis in humans and leads to the formation of a second skeleton of heterotopic bone. Presently, there is no effective treatment. Areas covered: In this review, the authors discuss heterozygous activating mutations in Activin receptor A, type I/activin-like kinase 2 (ACVR1/ALK2), a bone morphogenetic protein (BMP) type I receptor that are the genetic cause of FOP and reveal a promising pharmacologic target in the BMP signaling pathway. Despite these germline mutations, episodic disease activation is induced by soft tissue injury and resultant inflammatory triggers that are dependent on responding progenitor cells and a tissue microenvironment that supports heterotopic ossification. Expert opinion: Here, we review opportunities and challenges for the development of effective therapeutics for FOP. There are many potential approaches that may eventually be used to harness FOP. The long-term treatment of FOP is likely to involve not one, but several concomitant approaches that acknowledge molecular mechanisms involved in the induction and progression of the disease.

Original languageEnglish (US)
Pages (from-to)637-649
Number of pages13
JournalExpert Opinion on Orphan Drugs
Volume1
Issue number8
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Myositis Ossificans
Pharmaceutical Preparations
Type I Activin Receptors
Type I Bone Morphogenetic Protein Receptors
Activin Receptors
Heterotopic Ossification
Soft Tissue Injuries
Bone Morphogenetic Proteins
Germ-Line Mutation
Expert Testimony
Skeleton
Disease Progression
Phosphotransferases
Stem Cells
Bone and Bones
Mutation

Keywords

  • Bone morphogenetic protein receptors
  • Fibrodysplasia ossificans progressiva
  • Heterotopic endochondral ossification
  • Skeletal metamorphosis

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy
  • Pharmacology (medical)

Cite this

From mysteries to medicines : Drug development for fibrodysplasia ossificans progressiva. / Kaplan, Frederick S.; Pignolo, Robert; Shore, Eileen M.

In: Expert Opinion on Orphan Drugs, Vol. 1, No. 8, 01.01.2013, p. 637-649.

Research output: Contribution to journalReview article

@article{f64ea92619b3443dbb4f2816aee39b30,
title = "From mysteries to medicines: Drug development for fibrodysplasia ossificans progressiva",
abstract = "Introduction: Fibrodysplasia ossificans progressiva (FOP) is the most disabling disorder of skeletal metamorphosis in humans and leads to the formation of a second skeleton of heterotopic bone. Presently, there is no effective treatment. Areas covered: In this review, the authors discuss heterozygous activating mutations in Activin receptor A, type I/activin-like kinase 2 (ACVR1/ALK2), a bone morphogenetic protein (BMP) type I receptor that are the genetic cause of FOP and reveal a promising pharmacologic target in the BMP signaling pathway. Despite these germline mutations, episodic disease activation is induced by soft tissue injury and resultant inflammatory triggers that are dependent on responding progenitor cells and a tissue microenvironment that supports heterotopic ossification. Expert opinion: Here, we review opportunities and challenges for the development of effective therapeutics for FOP. There are many potential approaches that may eventually be used to harness FOP. The long-term treatment of FOP is likely to involve not one, but several concomitant approaches that acknowledge molecular mechanisms involved in the induction and progression of the disease.",
keywords = "Bone morphogenetic protein receptors, Fibrodysplasia ossificans progressiva, Heterotopic endochondral ossification, Skeletal metamorphosis",
author = "Kaplan, {Frederick S.} and Robert Pignolo and Shore, {Eileen M.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1517/21678707.2013.825208",
language = "English (US)",
volume = "1",
pages = "637--649",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - From mysteries to medicines

T2 - Drug development for fibrodysplasia ossificans progressiva

AU - Kaplan, Frederick S.

AU - Pignolo, Robert

AU - Shore, Eileen M.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Introduction: Fibrodysplasia ossificans progressiva (FOP) is the most disabling disorder of skeletal metamorphosis in humans and leads to the formation of a second skeleton of heterotopic bone. Presently, there is no effective treatment. Areas covered: In this review, the authors discuss heterozygous activating mutations in Activin receptor A, type I/activin-like kinase 2 (ACVR1/ALK2), a bone morphogenetic protein (BMP) type I receptor that are the genetic cause of FOP and reveal a promising pharmacologic target in the BMP signaling pathway. Despite these germline mutations, episodic disease activation is induced by soft tissue injury and resultant inflammatory triggers that are dependent on responding progenitor cells and a tissue microenvironment that supports heterotopic ossification. Expert opinion: Here, we review opportunities and challenges for the development of effective therapeutics for FOP. There are many potential approaches that may eventually be used to harness FOP. The long-term treatment of FOP is likely to involve not one, but several concomitant approaches that acknowledge molecular mechanisms involved in the induction and progression of the disease.

AB - Introduction: Fibrodysplasia ossificans progressiva (FOP) is the most disabling disorder of skeletal metamorphosis in humans and leads to the formation of a second skeleton of heterotopic bone. Presently, there is no effective treatment. Areas covered: In this review, the authors discuss heterozygous activating mutations in Activin receptor A, type I/activin-like kinase 2 (ACVR1/ALK2), a bone morphogenetic protein (BMP) type I receptor that are the genetic cause of FOP and reveal a promising pharmacologic target in the BMP signaling pathway. Despite these germline mutations, episodic disease activation is induced by soft tissue injury and resultant inflammatory triggers that are dependent on responding progenitor cells and a tissue microenvironment that supports heterotopic ossification. Expert opinion: Here, we review opportunities and challenges for the development of effective therapeutics for FOP. There are many potential approaches that may eventually be used to harness FOP. The long-term treatment of FOP is likely to involve not one, but several concomitant approaches that acknowledge molecular mechanisms involved in the induction and progression of the disease.

KW - Bone morphogenetic protein receptors

KW - Fibrodysplasia ossificans progressiva

KW - Heterotopic endochondral ossification

KW - Skeletal metamorphosis

UR - http://www.scopus.com/inward/record.url?scp=84896710829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896710829&partnerID=8YFLogxK

U2 - 10.1517/21678707.2013.825208

DO - 10.1517/21678707.2013.825208

M3 - Review article

VL - 1

SP - 637

EP - 649

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 8

ER -